'Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial' Response

Basit Öğe Kaydı
dc.authoridBaysal, Ayse/0000-0002-1487-7407
dc.authorwosiddoğukan, mevlüt/HJY-5235-2023
dc.contributor.authorBaysal, Ayse
dc.contributor.authorSagiroglu, Gonul
dc.contributor.authorDogukan, Mevlut
dc.contributor.authorOzkaynak, Ismail
dc.date.accessioned2024-06-12T11:19:48Z
dc.date.available2024-06-12T11:19:48Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractdose after neostigmine a routine reversal may prevent residual neuoutcome parameter of incidence of rNMB with other clinical studies may show external validity issues. In the Letter to the Editor, the authors have a request to explain these comparisons with other clinical studies; (3) The Letter to the Editor suggested that although their primary endpoint was the incidence of a train-of-four (TOF) ratio less than 0.9 at tracheal extubation, Baysal and her colleagues did not use TOF monitoring for extubation of the patients in their clinical study. They used only clinically apparent diaphragmatic movements for extubation. The authors of the Letter to the Editor, Neira-Somoza the administration of a lower dose of sugammadex to displace the use of neostigmine with a lower dose and earlier administration of sugammadex which is another future investigation of neuromuscular reversal agents.en_US
dc.identifier.endpage585en_US
dc.identifier.issn1089-9472
dc.identifier.issn1532-8473
dc.identifier.issue5en_US
dc.identifier.pmid36182245en_US
dc.identifier.startpage584en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25351
dc.identifier.volume37en_US
dc.identifier.wosWOS:000869141700005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Perianesthesia Nursingen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectResidual Neuromuscular Blockadeen_US
dc.subjectMulticenteren_US
dc.title'Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial' Responseen_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu